Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team..

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47.

PMID:
17106274
2.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
3.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540

Supplemental Content

Support Center